Avantec Vascular Chooses bioaccess™ For A First-In-Human Clinical Study In Latin America
[ORLANDO, FL, September 3, 2021] - Avantec Vascular Corporation (https://www.avantecvascular.com/), a company in the San Francisco Bay Area dedicated to advancing vascular therapies through innovation, has chosen Latin America as the destination for the first-in-human study of an innovative vascular device. bioaccess™ will help Avantec Vascular with the selection of a principal investigator, the submission of its regulatory dossier for the ministry of health approvals, and other activities related to carrying out the study.
Avantec Vascular Corporation is a wholly-owned subsidiary of Goodman Co. Ltd., headquartered in Nagoya, Japan. Goodman has facilities in Japan, Ireland, China, and the United States. Avantec, established in 1999, joined Goodman in 2002 and merged with Intella Interventional Systems in 2004. Nipro Corporation became a majority shareholder of Goodman in 2013 and subsequently made Goodman a wholly-owned subsidiary in 2014.
Avantec focused on minimally invasive therapeutic medical device technologies for current and future needs in the areas of cardiovascular, neurovascular, and peripheral vascular. Avantec develops cardiovascular, neurovascular, and peripheral vascular medical devices in Silicon Valley. Avantec strives to continuously advance innovative devices that address unmet clinical needs. Avantec plays a key role in the corporate global business development endeavor, employing our core strength in technology and product development to pursue new opportunities in satisfying unmet clinical needs.
Avantec has made significant investments to enhance Avantec’s future technology development and product pipelines including a vascular retrieval system, neurovascular/peripheral coils, peripheral atherectomy, and specialty coronary/peripheral drug-eluting stents (DES).
About Avantec Vascular
Avantec Vascular (https://www.avantecvascular.com/) provides innovative treatment solutions to offer longevity to human life through better health. The company's mission is to utilize its core competencies to develop and manufacture innovative next-generation medical device technologies and products that will improve the quality of life for patients.
About bioaccess™
bioaccess™ (www.bioaccessla.com) is a Colombia and US-based Contract Research Organization, regulatory and market access consulting company that delivers a full spectrum of offerings from bench to commercialization so that global pharmaceutical and medical device companies can have long-term success in Colombia, Brazil, Mexico, Argentina, and the rest of Latin America.
Media Contact:
bioaccess™
Julio G. Martinez-Clark,
Chief Executive Officer
jmclark@bioaccessla.com
